Type IIType II DiabetesDiabetes & EndocrinologyFamily PracticeNursingInternal MedicinePharmacyBlood DisordersBlood PressureDiabetesType 2 DiabetesGeneral HealthPrescription Drugs
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Sept. 24, 2015 (HealthDay News) -- Sleep-time ambulatory blood pressure (ABP) predicts new-onset diabetes, and ingestion of hypertension medications at bedtime is associated with reduced risk of new-onset diabetes, according to two studies published online Sept. 23 in Diabetologia.
Ramón C. Hermida, Ph.D., from the University of Vigo in Spain, and colleagues examined the prognostic value of clinic and ABP to predict new-onset diabetes in a cohort of 2,656 individuals without diabetes. The researchers found that during a median follow-up of 5.9 years, 190 participants developed type 2 diabetes. The most significant predictor of new-onset diabetes was sleep-time systolic ABP in a model adjusted for confounding variables. Per one-standard deviation decrease in sleep-time systolic ABP mean there was a 30 percent reduction in the risk of new-onset diabetes.
In a second study, Hermida and colleagues examined whether bedtime ingestion of hypertension medications correlated with reduction in the risk of new-onset diabetes. The trial included 2,012 patients with hypertension without diabetes. During a 5.9-year median follow-up, the researchers identified 171 patients who developed type 2 diabetes. Patients in the bedtime versus the morning-treatment group had significantly lower sleep-time BP mean, greater sleep-time relative BP decline, and lower prevalence of non-dipping at the final evaluation. After adjustment for confounding variables, they also had a significantly lower hazard ratio for new-onset diabetes (adjusted hazard ratio, 0.43).
"Ingestion of the entire daily dose of ≥1 BP-lowering medications at bedtime compared with ingestion of all such medications upon-awakening, results in significantly improved asleep ABP control and prevention of new-onset diabetes," Hermida and colleagues write in the second study.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 31, 2022
Read this Next
Other Trending Articles